Overview


The Gonorrhea Therapeutics Market refers to the global industry focused on the development, production, and distribution of medicines used to treat gonorrhea, a common sexually transmitted infection caused by bacteria. The market is driven by rising infection rates, increasing antibiotic resistance, new drug development, updated treatment guidelines, and growing public health awareness worldwide.

According to FutureWise analysis, the gonorrhea therapeutics market in 2026 is US$1.84 billion, and is expected to reach US$2.76 billion by 2036 at a CAGR of 4.14%. The gonorrhea therapeutics market is being driven by the rising prevalence of antibiotic-resistant strains of gonorrhea, which require more advanced treatment options. Additionally, increasing awareness of sexually transmitted infections (STIs) and the demand for effective treatment solutions are further fueling market growth. Ongoing research and development of novel antibiotics and combination therapies are expected to lead to steady market expansion in the coming years. 

Growth Drivers:

  • Increasing global prevalence of gonorrhea infections
  • Rising cases of antibiotic-resistant Neisseria gonorrhoeae
  • Growing awareness about sexually transmitted infections (STIs)
  • Government initiatives and public health screening programs
  • Advancements in antibiotic development and combination therapies

Key Trends:

  • Emergence of new antibiotic candidates targeting resistant strains
  • Use of combination therapies to improve treatment effectiveness
  • Integration of rapid diagnostic testing with treatment plans
  • Increased focus on antimicrobial resistance research and stewardship
  • Strategic partnerships between pharma companies and research institutions

Market Segmentation and Key Players:

The Gonorrhea Therapeutics Market is segmented by type of infection (uncomplicated and complicated cases), treatment type (monotherapy and dual therapy), route of administration (oral and injectable), gender (male and female), distribution channel (hospital, retail, and online pharmacies), and region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa). This segmentation highlights how treatment methods, patient groups, and regional demand influence market growth. Comprehensive segmentation details are provided in the Segmentation section below.

Major companies operating in the Gonorrhea Therapeutics market include Pfizer Inc., GlaxoSmithKline Plc, and Merck & Co., Inc.

Research Methodology:

The research methodology for the Gonorrhea Therapeutics Market by FutureWise Research employs a combination of primary and secondary sources. Secondary research includes industry reports and regulatory data, while primary research involves interviews with experts and healthcare professionals. The study employs market size estimation, data triangulation, and forecasting models to provide insights into trends, growth drivers, the competitive landscape, and future opportunities.

  • Hologic, Inc.
  • Merck & Co.
  • Pfizer Inc.
  • AstraZeneca
  • Danaher
  • Abbott
  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Lupin Pharmaceuticals
  • Teligent, Inc.
  • Bayer AG
  • GlaxoSmithKline Plc.
  • Novartis AG.
  • Allergan plc
  • Sanofi S.A.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Baxter International Inc.

(Note: The list of major players will be updated with the latest market scenario and trends)

Recent development of key players in the Gonorrhea Therapeutics Market: 

GlaxoSmithKline Plc.

  • February 2024 – Phase 3 trial results demonstrated the effectiveness of gepotidacin, achieving its non-inferiority goal compared to the current standard of care.
  • March 2025 – Gepotidacin received FDA approval under the brand name Blujepa for the treatment of uncomplicated urinary tract infections, establishing regulatory credibility.
  • August 2025 – The FDA has accepted a supplemental NDA for gepotidacin as a treatment for urogenital gonorrhea, granting it Priority Review status.

Hologic, Inc.

  • Hologic remains at the forefront of gonorrhea diagnostics with its highly sensitive Aptima Combo 2 assay, which is widely utilized for accurate detection. The company is also developing point-of-care nucleic acid amplification test (NAAT) platforms to enhance rapid and accessible STI testing worldwide.

Pfizer Inc.:

  • Pfizer plays a significant role in dual-therapy treatments by producing azithromycin, which is widely used in combination therapies for gonorrhea. The company is also developing multiplex diagnostic tools that can detect gonorrhea alongside other STIs to support more comprehensive screening.

Danaher:

  • Through its diagnostics subsidiaries, it is developing rapid diagnostic tools for gonorrhea. The company is developing microfluidic point-of-care devices to facilitate the rapid and efficient detection of STIs in various healthcare settings.

Abbott

  • Abbott is expanding its STI testing portfolio with automated, high-throughput diagnostic platforms. These technologies help hospitals and clinical labs efficiently identify gonorrhea and other infections, facilitating timely treatment.

Market Dynamics and Trends

  1. Attention is shifting towards oral, single-dose treatments that can effectively address resistant strains of Neisseria gonorrhoeae.
  2. Regulatory agencies are granting fast-track and priority review designations to expedite the approval process.
  3. Public–private partnerships are enhancing the global availability of new treatments, particularly in areas with a high disease burden.

By Gonococcal Infection

  • Uncomplicated Gonococcal Infection
  • Gonococcal Arthritis
  • Gonococcal Meningitis and Endocarditis

By Treatment

  • Monotherapy
  • Dual Therapy

By Route of Administration

  • Oral
  • Injectable

By Gender

  • Women
  • Men

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

Here’s a regional view of where the most progress is happening

North America

  • United States is the global leader in gonorrhea therapeutic development. Reasons: Government agencies, such as the NIH and BARDA, provide robust funding for programs aimed at addressing antibiotic resistance.
  • Headquarters of major pharmaceutical companies leading research and development, including GSK's U.S. operations and Innoviva/Entasis. Early access to clinical trial resources and priority review programs, such as the FDA's Qualified Infectious Disease Product (QIDP) designation and fast-track designations.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022 due to the region's sophisticated technologies being easily accessible and the excellent standards of its healthcare system. According to CDC estimates, in September 2022, the Center for Disease Control and Prevention (CDC) said that in 2021, 6,94,796 instances of gonorrhea were reported in the United States, a rise of 25.4% over the previous four years. Male cases of gonorrhea were more common than female cases in the United States. In addition, recent events like product launches, partnerships, mergers, and acquisitions among major industry participants are accelerating the market's expansion. For instance, the registrational Phase 3 clinical trial testing EVO100 for two potential additional indications—the prevention of chlamydia infection in women and the prevention of urogenital gonorrhea infection in women—was completed, according to an announcement made by Evofem Biosciences, Inc. in March 2022. As a result, patients receive superior therapies thanks to the pursuit of new product launches, which supports the expansion of the market in the region. Besides that, based on the route of administration, oral and injectables hold a market share of 62.8% and 37.2%, respectively in 2022.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Gonorrhea Therapeutics Market By Gonococcal Infection, By Treatment, By Route of Administration, By Gender, By Distribution Channel and By Region
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Gonorrhea Therapeutics Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Gonorrhea Therapeutics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Gonorrhea Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Gonorrhea Therapeutics Market, By Gonococcal Infection Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Uncomplicated Gonococcal Infection
        2. Gonococcal Arthritis
        3. Gonococcal Meningitis and Endocarditis

  • 8.   Gonorrhea Therapeutics Market, By Treatment Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Monotherapy
        2. Dual Therapy

  • 9.   Gonorrhea Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Oral
        2. Injectable

  • 10.   Gonorrhea Therapeutics Market, By Gender Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Women
        2. Men

  • 11.   Gonorrhea Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 12.   North America Gonorrhea Therapeutics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2026-2036

  • 13.   Latin America Gonorrhea Therapeutics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2026-2036

  • 14.   Europe Gonorrhea Therapeutics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2026-2036

  • 15.   Asia Pacific Gonorrhea Therapeutics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2026-2036

  • 16.   Middle East and Africa Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2026-2036

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Hologic, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. MerckCo., Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Danaher
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Abbott
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Becton Dickinson and Company
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. F. Hoffmann-La Roche Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Lupin Pharmaceuticals
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teligent, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Bayer AG
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. GlaxoSmithKline Plc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Novartis AG
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Allergan plc
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Sanofi S.A.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Mylan N.V.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Teva Pharmaceutical Industries Ltd.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Baxter International Inc.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client

FAQ


The gonorrhea therapeutics market includes industries that develop, produce, and distribute treatments for managing and curing gonorrhea, a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae.

Key drivers include the increase in global gonorrhea cases, rising antibiotic resistance, improved diagnosis rates, heightened public health awareness, and ongoing research on new treatment options.

Major end users include:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • These serve both institutional and outpatient needs.

The primary challenges include increasing antimicrobial resistance, a scarcity of new drug approvals, and obstacles in providing affordable therapies to underserved regions.

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

Related Market

Bipolar Disorder Therapeutics Market

Read More

Chronic Lymphocytic Leukemia Therapeutics Market

Read More

Genetic Disorder Therapeutics Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11